Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 May;65(5):1584–1592. doi: 10.1128/iai.65.5.1584-1592.1997

Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.

Y C Chang 1, R Cherniak 1, T R Kozel 1, D L Granger 1, L C Morris 1, L C Weinhold 1, K J Kwon-Chung 1
PMCID: PMC175178  PMID: 9125534

Abstract

The extracellular polysaccharide capsule of Cryptococcus neoformans is a well-recognized virulence factor. Strain 602 is an acapsular clinical isolate of unknown serotype which has been widely used in studies of virulence and host-parasite interactions. In previous studies, strain 602 was compared with genetically unrelated strains of various serotypes because the wild-type equivalent of strain 602 was not available. We created an encapsulated strain, TYCC38-602, by transforming strain 602 with the CAP64 gene which was isolated from a serotype D strain. Serological tests and chemical analysis of the major polysaccharide capsule of TYCC38-602 indicated that strain 602 was originally derived from a serotype A strain. Restoration of the ability to produce a capsule enabled strain 602 to cause fatal infection in mice, whereas the acapsular strain 602 remained avirulent. Capsule-restored yeast cells of strain 602 activated the human complement system and bound C3 fragments in a manner that is characteristic of encapsulated cryptococci. In addition, the capsule in TYCC38-602 masked the ability of the organism to induce tumor necrosis factor alpha and subsequent nitric oxide synthase production in primed macrophage-like cells. These results indicate that the lack of capsule in strain 602 is the reason for its inability to cause fatal infection. Moreover, the acapsular phenotype accounts for differences in various biological activities of strain 602 compared to encapsulated strains. The results also indicate that the gene product of CAP64 does not contribute to serotype specificity of capsules in C. neoformans.

Full Text

The Full Text of this article is available as a PDF (849.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belay T., Cherniak R. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect Immun. 1995 May;63(5):1810–1819. doi: 10.1128/iai.63.5.1810-1819.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bulmer G. S., Sans M. D. Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J Bacteriol. 1967 Nov;94(5):1480–1483. doi: 10.1128/jb.94.5.1480-1483.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang Y. C., Kwon-Chung K. J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994 Jul;14(7):4912–4919. doi: 10.1128/mcb.14.7.4912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chang Y. C., Penoyer L. A., Kwon-Chung K. J. The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun. 1996 Jun;64(6):1977–1983. doi: 10.1128/iai.64.6.1977-1983.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cherniak R., Morris L. C., Anderson B. C., Meyer S. A. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun. 1991 Jan;59(1):59–64. doi: 10.1128/iai.59.1.59-64.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cherniak R., Morris L. C., Belay T., Spitzer E. D., Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun. 1995 May;63(5):1899–1905. doi: 10.1128/iai.63.5.1899-1905.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Collins H. L., Bancroft G. J. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun. 1991 Nov;59(11):3883–3888. doi: 10.1128/iai.59.11.3883-3888.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dong Z. M., Murphy J. W. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun. 1995 Mar;63(3):770–778. doi: 10.1128/iai.63.3.770-778.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edman J. C., Kwon-Chung K. J. Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol Cell Biol. 1990 Sep;10(9):4538–4544. doi: 10.1128/mcb.10.9.4538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fine D. P., Marney S. R., Jr, Colley D. G., Sergent J. S., Des Prez R. M. C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972 Oct;109(4):807–809. [PubMed] [Google Scholar]
  11. Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S., Tannenbaum S. R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982 Oct;126(1):131–138. doi: 10.1016/0003-2697(82)90118-x. [DOI] [PubMed] [Google Scholar]
  12. Green S. J., Crawford R. M., Hockmeyer J. T., Meltzer M. S., Nacy C. A. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol. 1990 Dec 15;145(12):4290–4297. [PubMed] [Google Scholar]
  13. Hibbs J. B., Jr, Taintor R. R., Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 1987 Jan 23;235(4787):473–476. doi: 10.1126/science.2432665. [DOI] [PubMed] [Google Scholar]
  14. Keller R. G., Pfrommer G. S., Kozel T. R. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun. 1994 Jan;62(1):215–220. doi: 10.1128/iai.62.1.215-220.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kozel T. R., Cazin J. Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun. 1971 Feb;3(2):287–294. doi: 10.1128/iai.3.2.287-294.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kozel T. R. Virulence factors of Cryptococcus neoformans. Trends Microbiol. 1995 Aug;3(8):295–299. doi: 10.1016/s0966-842x(00)88957-x. [DOI] [PubMed] [Google Scholar]
  17. Kozel T. R., Wilson M. A., Murphy J. W. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun. 1991 Sep;59(9):3101–3110. doi: 10.1128/iai.59.9.3101-3110.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kozel T. R., Wilson M. A., Welch W. H. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun. 1992 Aug;60(8):3122–3127. doi: 10.1128/iai.60.8.3122-3127.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kwon-Chung K. J. A new genus, filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia. 1975 Nov-Dec;67(6):1197–1200. [PubMed] [Google Scholar]
  20. Kwon-Chung K. J., Edman J. C., Wickes B. L. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect Immun. 1992 Feb;60(2):602–605. doi: 10.1128/iai.60.2.602-605.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kwon-Chung K. J., Varma A., Edman J. C., Bennett J. E. Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J Med Vet Mycol. 1992;30(1):61–69. [PubMed] [Google Scholar]
  22. Liew F. Y., Li Y., Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol. 1990 Dec 15;145(12):4306–4310. [PubMed] [Google Scholar]
  23. Lorsbach R. B., Russell S. W. A specific sequence of stimulation is required to induce synthesis of the antimicrobial molecule nitric oxide by mouse macrophages. Infect Immun. 1992 May;60(5):2133–2135. doi: 10.1128/iai.60.5.2133-2135.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Macher A. M., Bennett J. E., Gadek J. E., Frank M. M. Complement depletion in cryptococcal sepsis. J Immunol. 1978 May;120(5):1686–1690. [PubMed] [Google Scholar]
  25. McGaw T. G., Kozel T. R. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun. 1979 Jul;25(1):262–267. doi: 10.1128/iai.25.1.262-267.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McGee Z. A., Clemens C. M. Effect of bacterial products on tumor necrosis factor production: quantitation in biological fluids or tissues. Methods Enzymol. 1994;236:23–31. doi: 10.1016/0076-6879(94)36005-7. [DOI] [PubMed] [Google Scholar]
  27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  28. Naslund P. K., Miller W. C., Granger D. L. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun. 1995 Apr;63(4):1298–1304. doi: 10.1128/iai.63.4.1298-1304.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  30. Stuehr D. J., Marletta M. A. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res. 1987 Nov 1;47(21):5590–5594. [PubMed] [Google Scholar]
  31. Varma A., Kwon-Chung K. J. DNA probe for strain typing of Cryptococcus neoformans. J Clin Microbiol. 1992 Nov;30(11):2960–2967. doi: 10.1128/jcm.30.11.2960-2967.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vecchiarelli A., Pietrella D., Dottorini M., Monari C., Retini C., Todisco T., Bistoni F. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol. 1994 Nov;98(2):217–223. doi: 10.1111/j.1365-2249.1994.tb06128.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wilson M. A., Kozel T. R. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect Immun. 1992 Mar;60(3):754–761. doi: 10.1128/iai.60.3.754-761.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Young B. J., Kozel T. R. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect Immun. 1993 Jul;61(7):2966–2972. doi: 10.1128/iai.61.7.2966-2972.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES